biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by KayakerBCon Aug 02, 2016 4:41pm

93 Views

Post# 25103908

RE:RE:RE:Think about this..

Jekyl Jr: There has been no data on humans yet.. or at least not in public.

Yet again we see how uninformed you are. It's not possible for BTI or a pharma to do clinical trials with the peptide without it being public information (not to mention a required license agreement). Clinical trials have to be negotiated with and accepted by the FDA (or other country equivalent) and are then publicly listed.

Bullboard Posts

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta